arthritis
Celltrion launches Humira biosimilar in US
July 7, 2023Medical Communications Chronic Diseases, Humira, Yuflyma, arthritis, celltrion
South Korean biopharmaceutical company Celltrion has announced that its US branch – Celltrion USA – has launched a Humira (adalimumab) …
NICE recommends Janssen’s active psoriatic arthritis drug
May 28, 2021Medical Communications Janssen, NICE, UK, arthritis
NICE have released a Final Appraisal Document (FAD) recommending Janssen’s tremfya (guselkumab) as a new option for treating active psoriatic …
Abbvie psoriatic arthritis drug approved for use in Scotland
May 11, 2021Manufacturing and Production AbbVie, NHS, arthritis, psoriatic arthritis
Abbvie’s RINVOQ (upadacitinib) drug, for the treatment of active psoriatic arthritis (PsA) in adults, has been approved for use in …
Johnson & Johnson’s arthritis drug shows promising results in Phase III trial
March 16, 2021Manufacturing and Production Janssen, Johnson & Johnson, PSA, Tremfya, arthritis
Johnson & Johnson’s TREMFYA treatment for active Psoriatic Arthritis (PsA) has returned positive results in its Phase III trial.
University of Glasgow and Lilly sign £4.6m immunological disease partnership
February 15, 2021Sales and Marketing Eli Lilly, University of Glasgow, arthritis, fibrosis, lilly, uofg
The University of Glasgow and Eli Lilly and Company have entered into a research collaboration, across four diseases, worth £4.6 …
Jyseleca secures European approval in rheumatoid arthritis
September 28, 2020Research and Development, Sales and Marketing Europe, Jyseleca, arthritis, pharma
The European Commission has awarded approval to Gilead and Galpagos for their oral JAK inhibitor Jyseleca (filgotinib) as a treatment …
AbbVie granted EU marketing authorisation for new arthritis drug
December 19, 2019Business Services AbbVie, EC, EU, arthritis, rheumatoid arthritis
AbbVie have announced that the European Commission (EC) have granted marketing authorisation for RINVOQ (upadacitnib). It’s a daily selective reversible …
Europe approves first subcutaneous version of biosimilar infliximab
November 26, 2019Manufacturing and Production, Sales and Marketing arthritis, biosimilars, celltrion, infliximab, pharma
The European Commission has chosen to authorise Celltrion Healthcare’s Remsima SC, a biosimilar of infliximab and the first subcutaneous formulation …
Eli Lilly’s Taltz shows superiority over AbbVie’s Humira
December 18, 2018Manufacturing and Production Eli Lilly, Humira, Taltz, arthritis, immune system
A study has found that Eli Lilly’s Taltz (ixekizumab) met the primary, and all secondary endpoints, in patients with active …
Top Ten most popular articles on Pharmafile.com this week
April 27, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eli Lilly, FDA, Fresenius, Shire, Takeda, arthritis, pharma
The year seems like it’s running away as we come to the end of April. It’s been a more tense …
Lilly dumps Hanmi’s rheumatoid arthritis med
February 20, 2018Manufacturing and Production, Sales and Marketing Eli Lilly, arthritis, hanmi, pharma
Eli Lilly and Hanmi signed an exclusive licensing and collaboration agreement to develop the Bruton’s tyrosine kinase (BTK) inhibitor, HM71224, …
Lilly gets second shot at application for ‘blockbuster’ arthritis drug
August 31, 2017Sales and Marketing Eli Lilly, arthritis, baricitinib, biotech, drugs, pharma, pharmaceutical
Earlier this year, Eli Lilly was on the receiving end of one of the most surprising setbacks in recent times …
Existing arthritis drug could save thousands in blood cancer treatment
August 3, 2017Research and Development University of Sheffield, arthritis, biotech, blood cancer, drugs, life sciences, medicine, pharma, pharmaceutical
Findings by researchers at the University of Sheffield have indicated that thousands of pounds could be saved in blood cancer …
Sanofi and Regeneron score FDA approval for arthritis
May 23, 2017Manufacturing and Production, Sales and Marketing FDA, Kevzara, arthritis, sarilumab
The FDA has awarded Sanofi and Regeneron’s Kevzara (sarilumab) approval for the treatment of moderate to severely active rheumatoid arthritis …
Roche says Phase III trials for giant cell arteritis drug met primary endpoint
June 6, 2016Research and Development, Sales and Marketing Roche, arthritis, drug trial
Cancer drugmaker Roche (SIX: ROG) said late stage trials for its drug to treat giant cell arteritis (GCA) met its …
Latest content
FibroFind appoints Lee Borthwick as CEO
